CRIS Current Research Information System

GARAJOVA, INGRID
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.145
EU - Europa 1.610
AS - Asia 698
AF - Africa 89
SA - Sud America 10
OC - Oceania 5
Totale 4.557
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.128
GB - Regno Unito 450
IT - Italia 305
CN - Cina 247
SE - Svezia 227
DE - Germania 192
SG - Singapore 170
VN - Vietnam 156
IN - India 85
IE - Irlanda 74
CH - Svizzera 71
RU - Federazione Russa 60
FR - Francia 59
ZA - Sudafrica 36
EE - Estonia 34
UA - Ucraina 34
TG - Togo 33
FI - Finlandia 27
BG - Bulgaria 18
JO - Giordania 15
BE - Belgio 14
CA - Canada 13
GR - Grecia 11
CI - Costa d'Avorio 8
NL - Olanda 8
NG - Nigeria 7
BR - Brasile 5
IR - Iran 5
TR - Turchia 5
AU - Australia 4
NI - Nicaragua 4
PT - Portogallo 4
CL - Cile 3
ES - Italia 3
HR - Croazia 3
KR - Corea 3
PL - Polonia 3
RO - Romania 3
AT - Austria 2
BD - Bangladesh 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ID - Indonesia 2
LB - Libano 2
PS - Palestinian Territory 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
AR - Argentina 1
EC - Ecuador 1
EG - Egitto 1
HK - Hong Kong 1
HU - Ungheria 1
JP - Giappone 1
LT - Lituania 1
MD - Moldavia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
UZ - Uzbekistan 1
Totale 4.557
Salva come PNG Salva come JPEG
Città #
Southend 410
Fairfield 283
Chandler 223
Ashburn 147
Singapore 146
Wilmington 137
Houston 131
Woodbridge 125
Seattle 120
Ann Arbor 118
Dong Ket 98
Princeton 97
Cambridge 96
Dublin 74
Bern 66
Bologna 52
Nanjing 46
Westminster 42
Padova 37
Berlin 35
Lomé 33
Santa Clara 31
Helsinki 27
Medford 21
New York 21
Beijing 20
Saint Petersburg 19
Sofia 18
Boardman 17
Turin 16
Amman 15
Shenyang 15
San Diego 14
Brussels 13
Changsha 13
Hebei 12
Jinan 12
Milan 12
Dearborn 11
Ravenna 11
Rome 10
Jacksonville 9
Toronto 9
Abidjan 8
Falls Church 8
Guangzhou 8
Olalla 8
Tianjin 8
Zhengzhou 8
Abeokuta 7
Frankfurt am Main 7
Mülheim 7
Torino 7
Nanchang 6
Norwalk 6
Redwood City 6
Ardabil 5
Bühl 5
Hangzhou 5
Jiaxing 5
London 5
Pune 5
Redmond 5
Bremen 4
Florence 4
Hefei 4
Istanbul 4
Kunming 4
Managua 4
Orange 4
Paris 4
Parma 4
Shanghai 4
Wuhan 4
Amsterdam 3
Athens 3
Cesena 3
Den Haag 3
Kuban 3
Lausanne 3
Los Angeles 3
Melbourne 3
Ningbo 3
Phoenix 3
Prineville 3
Rimini 3
São Paulo 3
Arzignano 2
Baoding 2
Bari 2
Bratislava 2
Chicago 2
Chongqing 2
Cinisello Balsamo 2
Dhaka 2
Empoli 2
Forlì 2
Gallipoli 2
Genoa 2
Haikou 2
Totale 3.100
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 262
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 170
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 168
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 165
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 146
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 141
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 140
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 134
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 130
Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases 130
Epigenetic and epitranscriptomic changes in colorectal cancer: diagnostic, prognostic, and treatment implications 124
In Reply 118
Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma 112
Circulating micrornas as dynamic biomarkers of disease progression during folfirinox therapy in unresectable pancreatic ductal adenocarcinoma (pdac) 111
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 111
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer 110
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 109
Antiapoptotic genes are overexpressed in the group of patients with locally advanced rectal adenocarcinomas who do not respond to neoadjuvant chemoradiotherapy 108
MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy 107
380 POSTER Association of miR21, miR31, miR143, miR145 and let-7a-1 levels with histopathologic features of colorectal cancer 102
c-Met as a Target for Personalized Therapy 102
EXPOSURE TO ASBESTOS: A PUTATIVE UNKNOWN RISK FACTOR FOR INTRAHEPATIC CHOLANGIOCARCINOMA 101
Altered expression of heat shock protein 110 (HSP110), hypoxia up- regulated 1 (HYOU1) and translationally controled tumor protein (TCTP) during colorectal cancer progression 99
Oxaliplatin in pre-treated patients: Maybe not the match point? 91
Neoadjuvant treatment in rectal cancer: actual status. 89
Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation. 89
D43Capecitabine and Regorafenib-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer 89
The role of microRNAs in resistance to current pancreatic cancer treatment: Translational studies and basic protocols for extraction and PCR analysis 87
Significant overexpression of Hsp110 gene during colorectal cancer progression 87
Second-line chemotherapy in biliary tract cancer patients. 87
Prognostic significance of tumor-infiltrating cytotoxic T-cells in colorectal cancer 86
Second-line chemotherapy in patients with biliary tract cancer. 85
The follow-up issues: from the necessity to the opportunity 84
L27MiR-21 expression as prognostic biomarker in extrahepatic but not intrahepatic radically resected cholangiocarcinomas 82
D44The overall survival of patients affected by metastatic colorectal cancer before and after “monoclonal antibodies era”: a monocentric retrospective study 79
Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer 79
MicroRNA profiling of primary pulmonary enteric adenocarcinoma shows similarity with lung cancer and pancreatic cancer 78
[Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma] 77
Feasibility of triplets (5-FU, oxaliplatin and irinotecan based) in front and subsequent lines of metastatic colorectal cancer patients. 76
[Gene expression profiling in prediction of tumor response to neoadjuvant concomitant chemoradiotherapy in patients with locally advanced rectal carcinoma: pilot study] 71
Occupational exposure to asbestos: a putative unknown risk factor for intrahepatic cholangiocarcinoma. 68
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 58
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 34
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development 31
Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials 27
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis 16
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 11
Synchronous and metachronous colorectal liver metastases: Impact of primary tumor location on patterns of recurrence and survival after hepatic resection 11
Should patients on levothyroxine therapy be screened for pancreatic cancer? 10
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 8
Totale 4.690
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.400
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.400
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020930 0 0 0 59 150 127 137 148 137 74 47 51
2020/2021579 115 36 18 17 6 32 26 33 58 32 21 185
2021/2022808 83 36 35 46 84 46 25 50 45 32 163 163
2022/20231.037 114 169 76 101 68 66 24 83 140 38 66 92
2023/2024269 39 40 9 32 11 51 9 17 11 14 22 14
2024/2025422 54 215 118 35 0 0 0 0 0 0 0 0
Totale 4.690